{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:56:45Z","timestamp":1776121005207,"version":"3.50.1"},"reference-count":102,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Cancer Institute of the National Institutes of Health","doi-asserted-by":"publisher","award":["CA097098"],"award-info":[{"award-number":["CA097098"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Cancer Institute of the National Institutes of Health","doi-asserted-by":"publisher","award":["CA233084"],"award-info":[{"award-number":["CA233084"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Cancer Institute of the National Institutes of Health","doi-asserted-by":"publisher","award":["CA267138"],"award-info":[{"award-number":["CA267138"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Cancer Institute of the National Institutes of Health","doi-asserted-by":"publisher","award":["CA262991"],"award-info":[{"award-number":["CA262991"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Castration resistant prostate cancer (CRPC) is responsive to androgen receptor (AR) axis targeted agents; however, patients invariably relapse with resistant disease that often progresses to neuroendocrine prostate cancer (NEPC). Treatment-related NEPC (t-NEPC) is highly aggressive with limited therapeutic options and poor survival outcomes. The molecular basis for NEPC progression remains incompletely understood. The MUC1 gene evolved in mammals to protect barrier tissues from loss of homeostasis. MUC1 encodes the transmembrane MUC1-C subunit, which is activated by inflammation and contributes to wound repair. However, chronic activation of MUC1-C contributes to lineage plasticity and carcinogenesis. Studies in human NEPC cell models have demonstrated that MUC1-C suppresses the AR axis and induces the Yamanaka OSKM pluripotency factors. MUC1-C interacts directly with MYC and activates the expression of the BRN2 neural transcription factor (TF) and other effectors, such as ASCL1, of the NE phenotype. MUC1-C also induces the NOTCH1 stemness TF in promoting the NEPC cancer stem cell (CSC) state. These MUC1-C-driven pathways are coupled with activation of the SWI\/SNF embryonic stem BAF (esBAF) and polybromo-BAF (PBAF) chromatin remodeling complexes and global changes in chromatin architecture. The effects of MUC1-C on chromatin accessibility integrate the CSC state with the control of redox balance and induction of self-renewal capacity. Importantly, targeting MUC1-C inhibits NEPC self-renewal, tumorigenicity and therapeutic resistance. This dependence on MUC1-C extends to other NE carcinomas, such as SCLC and MCC, and identify MUC1-C as a target for the treatment of these aggressive malignancies with the anti-MUC1 agents now under clinical and preclinical development.<\/jats:p>","DOI":"10.3390\/ijms24043719","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T03:28:46Z","timestamp":1676258926000},"page":"3719","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Dependence on MUC1-C in Progression of Neuroendocrine Prostate Cancer"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5743-8888","authenticated-orcid":false,"given":"Donald","family":"Kufe","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMra1701695","article-title":"Metastatic prostate cancer","volume":"378","author":"Sartor","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"a030593","DOI":"10.1101\/cshperspect.a030593","article-title":"Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies","volume":"9","author":"Puca","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrurol.2018.22","article-title":"Cellular plasticity and the neuroendocrine phenotype in prostate cancer","volume":"15","author":"Davies","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/PAS.0b013e318058a96b","article-title":"Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases","volume":"32","author":"Wang","year":"2008","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation","volume":"38","author":"Epstein","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1158\/0008-5472.CAN-19-2948","article-title":"Revisiting Immunotherapy: A Focus on Prostate Cancer","volume":"80","author":"Cha","year":"2020","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Rizzo, A., Mollica, V., Cimadamore, A., Santoni, M., Scarpelli, M., Giunchi, F., Cheng, L., Lopez-Beltran, A., Fiorentino, M., and Montironi, R. (2020). Is there a role for immunotherapy in prostate cancer?. Cells, 9.","DOI":"10.3390\/cells9092051"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kim, T.J., and Koo, K.C. (2020). Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155484"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1172\/JCI122819","article-title":"Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer","volume":"129","author":"Sharp","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41391-020-00309-w","article-title":"Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide","volume":"24","author":"Conteduca","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1158\/1078-0432.CCR-13-3296","article-title":"Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer","volume":"20","author":"Liu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_16","first-page":"PO.17.00029","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","volume":"1","author":"Abida","year":"2017","journal-title":"JCO Precis Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.6004\/jnccn.2021.0008","article-title":"NCCN Guidelines Insights: Prostate Cancer, Version 1.2021","volume":"19","author":"Schaeffer","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): A multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41391-019-0134-5","article-title":"MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer","volume":"22","author":"Nickols","year":"2019","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/1541-7786.MCR-19-1245","article-title":"Targeting RET Kinase in Neuroendocrine Prostate Cancer","volume":"18","author":"VanDeusen","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41467-019-14219-6","article-title":"MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer","volume":"11","author":"Yasumizu","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1073\/pnas.0304146101","article-title":"Gene expression profiling identifies clinically relevant subtypes of prostate cancer","volume":"101","author":"Lapointe","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/sj.bjc.6603944","article-title":"MUC-1 gene is associated with prostate cancer death: A 20-year follow-up of a population-based study in Sweden","volume":"97","author":"Fall","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Eminaga, O., Wei, W., Hawley, S.J., Auman, H., Newcomb, L.F., Simko, J., Hurtado-Coll, A., Troyer, D.A., Carroll, P.R., and Gleave, M.E. (2016). MUC1 expression by immunohistochemistry is associated with adverse pathologic features in prostate cancer: A mul-ti-institutional study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165236"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/pcan.2016.11","article-title":"MUC1 is upregulated in advanced prostate cancer and is an inde-pendent prognostic factor","volume":"19","author":"Genitsch","year":"2016","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neo.2017.06.006","article-title":"Overexpression of MUC1 and Genomic Alterations in Its Network Associate with Prostate Cancer Progression","volume":"19","author":"Lin","year":"2017","journal-title":"Neoplasia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/hyb.1984.3.223","article-title":"Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast Tumors","volume":"3","author":"Kufe","year":"1984","journal-title":"Hybridoma"},{"key":"ref_32","first-page":"263","article-title":"Monoclonal antibodies that react with epithelial membrane antigen","volume":"1","author":"Ormerod","year":"1984","journal-title":"J. Exp. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1073\/pnas.85.7.2320","article-title":"Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen","volume":"85","author":"Siddiqui","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"12820","DOI":"10.1016\/S0021-9258(18)37632-4","article-title":"A highly immunogenic region of a human poly-morphic epithelial mucin expressed by carcinomas is made up of tandem repeats","volume":"263","author":"Gendler","year":"1988","journal-title":"J. Biol. Chem."},{"key":"ref_35","first-page":"6966","article-title":"Frequent alteration of the DF3 tumor-associated antigen gene in primary human breast carcinomas","volume":"49","author":"Merlo","year":"1989","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.gene.2005.12.021","article-title":"Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16","volume":"373","author":"Duraisamy","year":"2006","journal-title":"Gene"},{"key":"ref_37","first-page":"671","article-title":"Evolution of the human MUC1 oncoprotein","volume":"31","author":"Duraisamy","year":"2007","journal-title":"Int. J. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/nrc2761","article-title":"Mucins in cancer: Function, prognosis and therapy","volume":"9","author":"Kufe","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1172\/JCI26705","article-title":"MUC1 cell surface mucin is a critical element of the mucosal barrier to infection","volume":"117","author":"McAuley","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-3-319-15856-3_4","article-title":"Transmembrane mucin expression and function in mmbryo implantation and placentation","volume":"216","author":"Constantinou","year":"2015","journal-title":"Adv. Anat. Embryol. Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"E6566","DOI":"10.1073\/pnas.1701129114","article-title":"Embryo implantation evolved from an an-cestral inflammatory attachment reaction","volume":"114","author":"Griffith","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Kufe, D. (2022). Emergence of MUC1 in mammals for adaptation of barrier epithelia. Cancers, 14.","DOI":"10.3390\/cancers14194805"},{"key":"ref_43","first-page":"12","article-title":"Chronic activation of MUC1-C in wound repair promotes progression to cancer stem cells","volume":"8","author":"Kufe","year":"2022","journal-title":"J. Cancer Metastasis Treat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/carcin\/bgaa082","article-title":"MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment","volume":"41","author":"Kufe","year":"2020","journal-title":"Carcinogenesis"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41388-017-0096-9","article-title":"MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells","volume":"37","author":"Rajabi","year":"2018","journal-title":"Oncogene"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrurol.2017.167","article-title":"The inflammatory microenvironment and microbiome in prostate cancer development","volume":"15","author":"Sfanos","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/pros.22814","article-title":"Epithelial-to-mesenchymal transition and estrogen receptor \u03b1 mediated epithelial dedifferentiation mark the development of benign prostatic hyperplasia","volume":"74","author":"Shao","year":"2014","journal-title":"Prostate"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1073\/pnas.0812666106","article-title":"A role for epitheli-al-mesenchymal transition in the etiology of benign prostatic hyperplasia","volume":"106","author":"Brossner","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4081\/aiua.2017.4.259","article-title":"The association between prostatitis and prostate cancer. Systematic review and meta-analysis","volume":"89","author":"Perletti","year":"2017","journal-title":"Arch. Ital. Urol. Androl."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/pros.22519","article-title":"MUC1-C oncoprotein confers andro-gen-independent growth of human prostate cancer cells","volume":"72","author":"Rajabi","year":"2012","journal-title":"Prostate"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","article-title":"The Master Neural Transcription Factor BRN2 Is an Androgen Receptor\u2013Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer","volume":"7","author":"Bishop","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ijc.2910210305","article-title":"Isolation of a human prostate carcinoma cell line (DU 145)","volume":"21","author":"Stone","year":"1978","journal-title":"Int. J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"650054","DOI":"10.3389\/fonc.2021.650054","article-title":"Enzalutamide-induced upregulation of PCAT6 promotes prostate cancer neuroendocrine differentiation by regulating miR-326\/HNRNPA2B1 axis","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1172\/JCI127961","article-title":"N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer","volume":"130","author":"Berger","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/iju.13526","article-title":"Clinical and molecular features of treatment-related neuroendocrine prostate cancer","volume":"25","author":"Akamatsu","year":"2018","journal-title":"Int. J. Urol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nrm.2016.8","article-title":"A decade of transcription factor-mediated reprogramming to pluripotency","volume":"17","author":"Takahashi","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_58","first-page":"10.32392\/biomed.18","article-title":"Somatic Pluripotent Genes in Tissue Repair, Developmental Disease, and Cancer","volume":"1","author":"Wollenzien","year":"2018","journal-title":"SPG BioMed"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev-cancerbio-030617-050224","article-title":"Lineage Plasticity in Cancer Progression and Treatment","volume":"2","author":"Shen","year":"2018","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.stem.2018.11.011","article-title":"Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance","volume":"24","author":"Gupta","year":"2019","journal-title":"Cell Stem Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1038\/onc.2014.442","article-title":"MUC1-C activates the TAK1 inflammatory pathway in colon cancer","volume":"34","author":"Takahashi","year":"2015","journal-title":"Oncogene"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7481","DOI":"10.1038\/s41598-017-07850-0","article-title":"MUC1-C activates EZH2 expression and function in human cancer cells","volume":"7","author":"Rajabi","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/onc.2016.439","article-title":"MUC1-C activates BMI1 in human cancer cells","volume":"36","author":"Hiraki","year":"2016","journal-title":"Oncogene"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"a026930","DOI":"10.1101\/cshperspect.a026930","article-title":"The Many Roles of BAF (mSWI\/SNF) and PBAF Complexes in Cancer","volume":"6","author":"Hodges","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cell.2017.08.002","article-title":"Genome Regulation by Polycomb and Trithorax: 70 Years and Counting","volume":"171","author":"Schuettengruber","year":"2017","journal-title":"Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1101\/gad.326066.119","article-title":"Dangerous liaisons: Interplay between SWI\/SNF, NuRD, and Polycomb in chromatin regulation and cancer","volume":"33","author":"Bracken","year":"2019","journal-title":"Genes Dev."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Clapier, C. (2021). Sophisticated Conversations between Chromatin and Chromatin Remodelers, and Dissonances in Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115578"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.gde.2017.02.004","article-title":"Mammalian SWI\/SNF complexes in cancer: Emerging therapeutic opportunities","volume":"42","author":"Pierre","year":"2017","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ng.3746","article-title":"SMARCB1-mediated SWI\/SNF complex function is essential for enhancer regulation","volume":"49","author":"Wang","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/ng.3744","article-title":"ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice","volume":"49","author":"Mathur","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1016\/j.celrep.2018.05.097","article-title":"The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II","volume":"23","author":"Trizzino","year":"2018","journal-title":"Cell Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.molcel.2018.06.040","article-title":"Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis","volume":"71","author":"Sandoval","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1158\/0008-5472.CAN-20-2588","article-title":"MUC1-C Activates the BAF (mSWI\/SNF) Complex in Prostate Cancer Stem Cells","volume":"81","author":"Hagiwara","year":"2021","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-cellbio-051809-102012","article-title":"Chromatin regulatory mechanisms in pluripotency","volume":"26","author":"Lessard","year":"2010","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13072-019-0264-y","article-title":"The BAF complex in development and disease","volume":"12","author":"Alfert","year":"2019","journal-title":"Epigenet. Chromatin"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1073\/pnas.0812889106","article-title":"An embryonic stem cell chromatin remodeling complex, esBAF, is essential for embryonic stem cell self-renewal and pluripotency","volume":"106","author":"Ho","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"E6457","DOI":"10.1073\/pnas.1614529113","article-title":"Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer","volume":"113","author":"Stoyanova","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.7150\/ijbs.16349","article-title":"Insights into the Nanog gene: A propeller for stemness in primitive stem cells","volume":"12","author":"Zhang","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.molcel.2014.06.028","article-title":"Re-quirement for PBAF in transcriptional repression and repair at DNA breaks in actively transcribed regions of chromatin","volume":"55","author":"Kakarougkas","year":"2014","journal-title":"Mol. Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1021\/acschembio.7b00541","article-title":"BAF180: Its Roles in DNA Repair and Consequences in Cancer","volume":"12","author":"Hopson","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.isci.2019.04.027","article-title":"PBRM1 Regulates Stress Response in Epithelial Cells","volume":"15","author":"Porter","year":"2019","journal-title":"Iscience"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1101\/gad.1323805","article-title":"PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes","volume":"19","author":"Yan","year":"2005","journal-title":"Genes Dev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1158\/0008-5472.CAN-09-2089","article-title":"BRD7, a Subunit of SWI\/SNF Complexes, Binds Directly to BRCA1 and Regulates BRCA1-Dependent Transcription","volume":"70","author":"Harte","year":"2010","journal-title":"Cancer Res"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1038\/s41388-021-01899-y","article-title":"MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells","volume":"40","author":"Hagiwara","year":"2021","journal-title":"Oncogene"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.molcel.2017.04.006","article-title":"DNA Damage in Stem Cells","volume":"66","author":"Vitale","year":"2017","journal-title":"Mol. Cell"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Tanabe, A., and Sahara, H. (2020). The Metabolic Heterogeneity and Flexibility of Cancer Stem Cells. Cancers, 12.","DOI":"10.3390\/cancers12102780"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","article-title":"NRF2 and the Hallmarks of Cancer","volume":"34","author":"Chapman","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/carcin\/bgaa039","article-title":"NRF2 as a regulator of cell metabolism and inflammation in cancer","volume":"41","author":"He","year":"2020","journal-title":"Carcinogenesis"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"9433","DOI":"10.1073\/pnas.1821323116","article-title":"Cystine\/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intra-cellular redox balance","volume":"116","author":"Lim","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1158\/1541-7786.MCR-21-0672","article-title":"MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells","volume":"20","author":"Bhattacharya","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.stem.2021.07.001","article-title":"Establishment, maintenance, and recall of inflammatory memory","volume":"28","author":"Larsen","year":"2021","journal-title":"Cell Stem. Cell"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e2029298","DOI":"10.1080\/2162402X.2022.2029298","article-title":"MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer","volume":"11","author":"Hagiwara","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"a028555","DOI":"10.1101\/cshperspect.a028555","article-title":"Responses to Cytokines and Interferons that Depend upon JAKs and STATs","volume":"10","author":"Stark","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","article-title":"Discovery of IDO1 Inhibitors: From Bench to Bedside","volume":"77","author":"Prendergast","year":"2017","journal-title":"Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e1486353","DOI":"10.1080\/2162402X.2018.1486353","article-title":"Up-regulation of tryptophanyl-tRNA synthethase adapts human cancer cells to nutritional stress caused by tryptophan degra-dation","volume":"7","author":"Adam","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e1016700","DOI":"10.1080\/2162402X.2015.1016700","article-title":"Reprogramming the tumor microenvironment: Tumor-induced immu-nosuppressive factors paralyze T cells","volume":"4","author":"Wu","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.molcel.2020.10.033","article-title":"Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers","volume":"80","author":"Rubin","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccell.2019.06.005","article-title":"Pan-cancer convergence to a small-cell neuroendocrine phenotype that shares susceptibilities with hematological malig-nancies","volume":"36","author":"Balanis","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/carcin\/bgab097","article-title":"MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas","volume":"43","author":"Luan","year":"2021","journal-title":"Carcinogenesis"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1158\/1541-7786.MCR-22-0165","article-title":"Dependence on the MUC1-C oncoprotein in classic, variant and non-neuroendocrine small cell lung cancer","volume":"20","author":"Fushimi","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1038\/s41388-022-02361-3","article-title":"Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment","volume":"41","author":"Morimoto","year":"2022","journal-title":"Oncogene"},{"key":"ref_102","first-page":"e99880","article-title":"Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate","volume":"3","author":"Panchamoorthy","year":"2018","journal-title":"J. Clin. Investig."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3719\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:33:04Z","timestamp":1760121184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":102,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24043719"],"URL":"https:\/\/doi.org\/10.3390\/ijms24043719","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]}}}